Janssen Biotech (Johnson & Johnson)

Janssen Biotech, Inc. is a Pennsylvania corporation whose principal place of business is listed as 800 Ridgeview Drive, Horsham, Pennsylvania. It operates within Johnson & Johnson’s pharmaceutical organization, although the legal entity is distinct from the broader Johnson & Johnson Innovative Medicine brand. [1] [3]

The entity’s biotechnology lineage runs through Centocor. Johnson & Johnson’s corporate timeline records the acquisition of Centocor in 1999, while a Johnson & Johnson announcement identifies Janssen Biotech as formerly Centocor Ortho Biotech. The latter company was associated with REMICADE (infliximab), an anti-tumor-necrosis-factor therapy used in inflammatory diseases and reviewed by the U.S. Food and Drug Administration for pediatric ulcerative colitis. [2] [4]

The name “Janssen” also reflects a separate but connected historical lineage. Johnson & Johnson says Dr. Paul Janssen founded Janssen Pharmaceutica in Belgium in 1953, and that Johnson & Johnson acquired the company in 1961; in 2010, Johnson & Johnson’s pharmaceutical companies adopted the shared Janssen identity. In September 2023, that broader pharmaceutical organization became Johnson & Johnson Innovative Medicine. [3]

Johnson & Johnson describes Innovative Medicine’s current therapeutic areas as oncology, immunology, neuroscience, cardiopulmonary disease and specialty ophthalmology. Its corporate timeline identifies Janssen Biotech’s 2015 DARZALEX (daratumumab) launch as the first human anti-CD38 monoclonal antibody available for multiple myeloma, illustrating the company’s continuing association with biologic and antibody-based medicines. The Janssen Biotech entity is included here because it is the Johnson & Johnson operating company named in biopharmaceutical collaboration and commercialization agreements, including those connected with cell-therapy development. [3] [4]